The choice of CHF drugs for these patients should be aimed at changing the course of the disease. It is reassuring to see that at least in the Coreg trials, diabetics at high risk for heart failure seemed to benefit as much as nondiabetics from nonselective beta-blockers. These trials and medical studies have been re-written in plain English. I am not a doctor. Use the ID numbers at the end of each article to search MedLine for the complete summary.
All original copyrights apply.
No information on this page should be used by any person to affect their medical treatment in any way.